Endo (NDOI) Completes International Pharmaceuticals Business Divestiture

Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc.

Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid at closing, approximately $11 million related to certain permitted holdbacks, and up to $15 million in future payments contingent upon the achievement of certain milestones.

You May Also Be Interested In

• Ancora pressures H.B. Fuller board to explore strategic alternatives
• Encompass Health plans two hospitals in Montgomery County, Texas
• Biomerica files for 1.4M share offering by selling stockholders